If your GP has mentioned MRCP, or a consultant has asked you to have one, the short version is this. MRCP is a specialised MRI that produces a clean, glowing map of the bile ducts and the pancreatic duct without any needles going near them. It replaced diagnostic ERCP more than a decade ago and, in 2026, is the first-line test for suspected duct stones, primary sclerosing cholangitis, pancreatic cystic lesions and unexplained upper abdominal pain after gallbladder removal.
This piece explains what MRCP shows, what it does not, and how it fits alongside CT, endoscopic ultrasound and ERCP in current UK practice.
One-line answer
MRCP is a 30-minute MRI that shows the biliary tree and pancreatic duct as bright fluid against dark tissue, without radiation and usually without contrast - the modern first-line test for suspected duct stones, strictures, IPMN and pancreatic ductal disease.
What MRCP actually is
MRCP stands for magnetic resonance cholangiopancreatography. Under the bonnet it is a standard 1.5T or 3T MRI, but the sequences are chosen to do one job - make static fluid look bright and everything else look dark. The workhorse is heavily T2-weighted imaging, often combined with a single-shot thick-slab MIP that gives the classic tree-shaped picture radiologists use to talk to hepatobiliary surgeons.
Because bile in the ducts and pancreatic juice in the pancreatic duct are essentially static fluid, they light up. The liver, the pancreatic parenchyma, the duodenum and the surrounding fat suppress into a dark background. What you get is a non-invasive cast of the biliary system that a decade ago required a duodenoscope, a cannula in the ampulla of Vater, and iodinated contrast injected retrogradely.
Most MRCP protocols use no intravenous contrast at all. Contrast is added only when the radiologist also needs to assess the liver parenchyma, a suspected pancreatic mass, or wants to use a hepatobiliary-specific agent such as gadoxetate to see bile physiology in real time.
The clinical questions MRCP answers
MRCP is not a general "look at my belly" scan. It is a targeted test for a defined set of clinical questions. In UK practice in 2026 those are:
- Choledocholithiasis - stones in the common bile duct. Ultrasound suggests a dilated duct; blood tests show a raised alkaline phosphatase and bilirubin; the question is whether there is a stone stuck at the ampulla. MRCP answers this without radiation and with sensitivity above 90 per cent for stones over 6 mm.
- Primary sclerosing cholangitis (PSC). The characteristic beaded, multifocal narrowing of intra and extrahepatic ducts is what MRCP is best at showing. It has largely replaced ERCP for PSC diagnosis and for annual surveillance.
- IPMN of the pancreas. Cystic pancreatic lesions with communication to the pancreatic duct. MRCP shows the cyst, the communication, the presence of mural nodules and any main-duct dilation - the features that decide surgery versus surveillance.
- Pancreatic mass staging. When CT has picked up a suspicious pancreatic lesion, MRCP with contrast and diffusion-weighted imaging characterises it further, defines the vascular relationship, and looks for satellite lesions in the liver.
- Primary biliary changes. Autoimmune cholangiopathies, IgG4-related disease, and post-inflammatory strictures show characteristic MRCP patterns that guide biopsy or empirical treatment.
- Post-cholecystectomy pain. The gallbladder is out, but the pain came back. MRCP looks for a retained stone in the duct, a bile leak from the cystic duct stump, or a benign biliary stricture from the surgery.
MRCP vs ERCP vs endoscopic ultrasound
These three tests get confused because they all look at the same anatomy. They are not interchangeable.
| Test | What it does | Invasive? | Role in 2026 |
|---|---|---|---|
| MRCP | Cross-sectional imaging of ducts and pancreas | No | First-line diagnostic - the map |
| Endoscopic ultrasound (EUS) | High-resolution ultrasound from inside the duodenum, with option to biopsy | Yes - endoscopy under sedation | Second-line when MRCP is equivocal, or for cyst fluid sampling and mass biopsy |
| ERCP | Endoscope with a cannula into the ampulla, allowing therapy | Yes - endoscopy under sedation, with a 3 to 5 per cent complication rate | Almost exclusively therapeutic in 2026 - stone extraction, stent placement, sphincterotomy |
The pattern most hepatobiliary units follow is: MRCP first to answer the diagnostic question, then EUS if the answer is unclear or a biopsy is needed, then ERCP only when there is something to treat. Sending a patient straight to ERCP for diagnosis is now considered poor practice - the complication rate is too high for a test we have a non-invasive alternative for.
The protocol - what actually happens on the day
MRCP is one of the easier MRI experiences for a patient. You are asked to fast for four to six hours beforehand, which reduces fluid in the stomach and duodenum and gives cleaner images. Regular medications are usually fine with a small sip of water - check with the unit.
You lie supine on the MRI table, feet-first. A body coil is placed across the upper abdomen. The scan runs for 25 to 45 minutes and requires you to hold your breath, briefly, several times - the radiographer will coach you through this. Some units use a prone position for specific cases. If contrast is being given, a cannula goes in the arm before you start.
For detailed pancreatic duct imaging - typically for suspected chronic pancreatitis, IPMN follow-up or pancreatic ductal anomalies - the radiologist may add secretin-stimulated MRCP. Secretin is a hormone given intravenously that briefly increases pancreatic fluid output, distending the pancreatic duct so subtle strictures and side-branch anatomy become visible. It adds 15 to 20 minutes and is well tolerated.
What the report describes
A good MRCP report reads systematically through the biliary and pancreatic system and comments on:
- Duct calibre. Common bile duct diameter (upper limit around 7 mm in an intact gallbladder, wider after cholecystectomy), pancreatic duct calibre (upper limit around 3 mm in the head).
- Stones. Number, size, location - usually described as filling defects in the T2-bright bile.
- Strictures. Location, length, appearance - smooth versus irregular, single versus multiple, benign-looking versus suspicious.
- Masses. Any focal lesion in the liver, gallbladder, ampulla or pancreas, with size, signal characteristics and enhancement pattern if contrast was used.
- Cystic lesions. Size, location, unilocular versus multilocular, presence of septations or mural nodules, communication with the pancreatic duct.
- Ancillary findings. Liver parenchyma, spleen, adrenals, kidneys and visible bowel loops all get a line each.
The report ends with an impression and, when relevant, a recommendation - repeat imaging in six months, refer to EUS, refer to hepatobiliary MDT.
